Methods for treating inflammation-mediated conditions of the eye
AssigneeOculex Pharmaceuticals, Inc.
InventorsVernon G. Wong, Mae W. L. Hu
Life of this patent
Estimating the term…
Abstract
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
Claims42
A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours, and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 μg/ml dexamethasone within about 6 hours and maintains a concentration equivalent to at least about 0.01 μg/ml dexamethasone for at least about three weeks.
A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting a bioerodible solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.2 μg/ml dexamethasone within about 6 hours, and maintains a concentration equivalent to at least about 0.01 μg/ml dexamethasone for at least about three weeks.
A solid bioerodible implant for treating an inflammation-mediated condition of the eye, consisting essentially of:
- dexamethasone particles entrapped within a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the dexamethasone makes up between about 50 percent by weight and about 80 percent by weight of the implant, and wherein the implant releases at least about 10% of the drug load within 1 week when measured under infinite sink conditions in vitro.
A solid bioerodible implant for treating an inflammation-mediated condition of the eye, the implant consisting essentially of:
- dexamethasone particles entrapped within a polyactic acid polyglycolic acid (PLGA) copolymer matrix, wherein the dexamethasone makes up between about 50 percent by weight and about 80 percent by weight of the implant, and wherein the implant releases at least about 15% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.
A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant releases at least about 15% of the steroidal anti-inflammatory agent within 2 weeks when measured under infinite sink conditions in vitro.
Dependencies are inferred from the claim text.